J&J CFO Says 3Q Earnings Beat Driven by Actelion Deal

The transcript discusses a company's strong financial performance, driven by a 10% increase in sales and a 13% rise in earnings, surpassing market expectations. Key growth factors include recent acquisitions, such as Actelion, and robust performance in the pharmaceutical sector, particularly in immunology and oncology. The medical devices segment, bolstered by the acquisition of Abbott Medical Optics, shows stable growth despite weather-related disruptions. The company is also reviewing its diabetes device business, considering strategic options for its future.

What factors contributed to the stability and growth of the medical devices segment?

What strategic decisions are being made regarding the diabetes device business?